Bokvist KB, et al. - Among 151 patients with inadequately controlled type 2 diabetes mellitus ± metformin, researchers desired to know whether a 4-week course of 14 mg weekly GLP-1 agonist LY2428757 combined with 3 mg or 2 mg daily gastrin analogue TT223 (LY+TT223) results in long-term glycaemic changes. Study participants were randomized to a 4-week course of LY+TT223 (3 mg), LY+TT223 (2 mg), LY+TT223 placebo (LY-only) or LY placebo+TT223 placebo (placebo). Change in HbA1c from baseline to 5 months after completion of therapy (ie, at 6 months) and safety and tolerability with LY+TT223 vs LY-only was the primary objective. During the active treatment phase, LY groups exhibited reductions in HbA1c. During the follow-up phase, these did not persist. Findings suggested that combination therapy with GLP-1+gastrin has not improved glycaemic control vs GLP-1 alone. Nausea and vomiting were the most common adverse events in this analysis.